Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy

Journal of Infection and Chemotherapy

Volumn 20, Issue 10, 2014, Pages 602-606

  Jo, Kyung Wook ^a   Kim, Sunyoung ^b   Lee, Jung Yeon ^c   Lee, Sang Do ^a   Kim, Woo Sung ^a   Kim, Dong Soon ^a   Shim, Tae Sun ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Konkuk University   (South Korea)

Author keywords

Clofazimine; Linezolid; MAC; Moxifloxacin; Rifabutin

Indexed keywords

ADULT; ANTIBIOTIC THERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM AVIUM COMPLEX; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; DRUG COMBINATION; LUNG DISEASES; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RETREATMENT; RETROSPECTIVE STUDY; TREATMENT FAILURE;

ANTIINFECTIVE AGENT; CLOFAZIMINE; LINEZOLID; MOXIFLOXACIN; QUINOLONE DERIVATIVE; RIFABUTIN;

AGED; ANTI-BACTERIAL AGENTS; CLOFAZIMINE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; HUMANS; LINEZOLID; LUNG DISEASES; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RETREATMENT; RETROSPECTIVE STUDIES; RIFABUTIN; TREATMENT FAILURE;

EID: 84908066150     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2014.05.010     Document Type: Article

References (34)

1. H.B. Xu, R.H. Jiang, and L. Li Treatment outcomes for Mycobacterium avium complex: a systematic review and meta-analysis Eur J Clin Microbiol Infect Dis 33 2014 347 358
2. J.W. Yoo, K.W. Jo, M.N. Kim, S.D. Lee, W.S. Kim, and D.S. Kim Increasing trend of isolation of non-tuberculous mycobacteria in a tertiary university hospital in South Korea Tuberc Respir Dis 72 2012 409 415
3. W.J. Koh, B.H. Jeong, K. Jeon, N.Y. Lee, K.S. Lee, and S.Y. Woo Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M avium complex lung disease 142 2012 1482 1488 http://www.ncbi.nlm.nih.gov.libproxy.amc.seoul.kr:8000/pubmed/?term=chest+2012+142+1482Chest
4. W.J. Koh, B.H. Jeong, K. Jeon, S.Y. Lee, and S.J. Shin Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease Am J Respir Crit Care Med 186 2012 797 802
5. S.K. Field, D. Fisher, and R.L. Cowie Mycobacterium avium complex pulmonary disease in patients without HIV infection Chest 126 2004 566 581
6. D.E. Griffith, T. Aksamit, B.A. Brown-Elliott, A. Catanzaro, C. Daley, and F. Gordin An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases Am J Respir Crit Care Med 175 2007 367 416
7. Y. Kobashi, T. Matsushima, and M. Oka A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease Respir Med 101 2007 130 138
8. D.E. Griffith, B.A. Brown-Elliott, B. Langsjoen, Y. Zhang, X. Pan, and W. Girard Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease Am J Respir Crit Care Me 174 2006 928 934
9. Definitions and reporting framework for tuberculosis - 2013 revision. http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345-eng.pdf [07.01.14, date last accessed].
10. S.K. Field, and R.L. Cowie Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine Chest 124 2003 1482 1486
11. W.J. Koh, G. Hong, S.Y. Kim, B.H. Jeong, H.Y. Park, and K. Jeon Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen Antimicrob Agents Chemother 57 2013 2281 2285
12. R.J. Wallace Jr., B.A. Brown, D.E. Griffith, W. Girard, and K. Tanaka Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection J Infect Dis 171 1995 747 750
13. B.A. Brown-Elliott, C.J. Crist, L.B. Mann, R.W. Wilson, and R.J. Wallace Jr. In vitro activity of linezolid against slowly growing nontuberculous mycobacteria Antimicrob Agents Chemother 47 2003 1736 1738
14. C. Cavusoglu, I. Soyler, and P. Akinci Activities of Linezolid against nontuberculous mycobacteria New Microbiol 30 2007 411 414
15. G. Chatte, G. Panteix, M. Perrin-Fayolle, and Y. Pacheco Aerosolized interferon gamma for Mycobacterium avium-complex lung disease Am J Respir Crit Care Med 152 1995 1094 1096
16. M.C. Cholo, H.C. Steel, P.B. Fourie, W.A. Germishuizen, and R. Anderson Clofazimine: current status and future prospects J Antimicrob Chemother 67 2012 290 298
17. J.W. Yoo, J. Lyu, S.D. Lee, W.S. Kim, D.S. Kim, and T.S. Shim Clinical experience of using clofazimine to treat multidrug-resistant tuberculosis [Correspondence] Int J Tuberc Lung Dis 17 2013 1243 1244
18. J. van Ingen, S.E. Totten, N.K. Helstrom, L.B. Heifets, M.J. Boeree, and C.L. Daley In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease Antimicrob Agents Chemother 56 2012 6324 6327
19. C. Sano, Y. Tatano, T. Shimizu, S. Yamabe, K. Sato, and H. Tomioka Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium Int J Antimicrob Agents 37 2011 296 301
20. A. Soman, D. Honeybourne, J. Andrews, G. Jevons, and R. Wise Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy J Antimicrob Chemother 44 1999 835 838
21. D.E. Griffith, B.A. Brown, W.M. Girard, and R.J. Wallace Jr. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease Clin Infect Dis 21 1995 594 598
22. D.E. Griffith, B.A. Brown, and R.J. Wallace Jr. Varying doses of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus-negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease Clin Infect Dis 23 1996 1321 1322
23. D.E. Griffith, and T.R. Aksamit Therapy of refractory nontuberculous mycobacterial lung disease Curr Opin Infect Dis 25 2012 218 227
24. C.L. Woodley, and J.O. Kilburn In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin Am Rev Respir Dis 126 1982 586 587
25. G. Sotgiu, R. Centis, L. D'Ambrosio, J.W. Alffenaar, H.A. Anger, and J.A. Caminero Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis Eur Respir J 40 2012 1430 1442
26. E.C. Nannini, M. Keating, P. Binstock, G. Samonis, and D.P. Kontoyiannis Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine J Infect 44 2002 201 203
27. I.N. Park, S.B. Hong, Y.M. Oh, M.N. Kim, C.M. Lim, and S.D. Lee Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis J Antimicrob Chemother 58 2006 701 704
28. W.J. Koh, Y.R. Kang, K. Jeon, O.J. Kwon, J. Lyu, and W.S. Kim Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients J Antimicrob Chemother 67 2012 1503 1507
29. P.K. Lam, D.E. Griffith, T.R. Aksamit, S.J. Ruoss, S.M. Garay, and C.L. Daley Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease Am J Respir Crit Care Med 173 2006 1283 1289
30. Y.S. Sim, H.Y. Park, K. Jeon, G.Y. Suh, O.J. Kwon, and W.J. Koh Standardized combination antibiotic treatment of Mycobacterium avium complex lung disease Yonsei Med J 51 2010 888 894
31. E.Y. Kim, S.Y. Chi, I.J. Oh, K.S. Kim, Y.I. Kim, and S.C. Lim Treatment outcome of combination therapy including clarithromycin for Mycobacterium avium complex pulmonary disease Korean J Intern Med 26 2011 54 59
32. Y. Kohno, H. Ohno, Y. Miyazaki, Y. Higashiyama, K. Yanagihara, and Y. Hirakata In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan Antimicrob Agents Chemother 51 2007 4071 4076
33. R.E. Chaisson, P. Keiser, M. Pierce, W.J. Fessel, J. Ruskin, and C. Lahart Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection AIDS 11 1997 311 317
34. L.E. Bermudez, C.B. Inderlied, P. Kolonoski, M. Petrofsky, P. Aralar, and M. Wu Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium Antimicrob Agents Chemother 45 2001 217 222